Skip to main content

Table 2 Patients’ baseline characteristics according to chemotherapy regimen and age

From: Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results

  Age <70 years Age ≥70 years Age <75 years Age ≥75 years
Characteristic Monotherapy (n = 105) Doublet (n = 1165) Monotherapy (n = 104) Doublet (n = 367) Monotherapy (n = 146) Doublet (n = 1396) Monotherapy (n = 63) Doublet (n = 136)
Gender, n (%)         
 Male 60 (57) 739 (63) 60 (58) 234 (64) 84 (58) 888 (64) 36 (57) 85 (62)
 Female 45 (43) 426 (37) 44 (42) 133 (36) 62 (42) 508 (36) 27 (43) 51 (38)
Median age, years (range) 62 (23–69) 61 (19–69) 76 (70–100) 73 (70–85) 65 (23–74) 63 (19–74) 78 (75–100) 77 (75–85)
ECOG performance status, n (%) (n = 103) (n = 1144) (n = 101) (n = 362) (n = 142) (n = 1372) (n = 62) (n = 134)
 0 52 (50) 435 (38) 38 (38) 112 (31) 67 (47) 514 (37) 23 (37) 33 (25)
 1 38 (37) 599 (52) 48 (48) 199 (55) 56 (39) 719 (52) 30 (48) 79 (59)
 2 11 (11) 108 (9) 13 (13) 41 (11) 17 (12) 129 (9) 7 (11) 20 (15)
 3 2 (2) 2 (<1) 2 (2) 9 (2) 2 (1) 9 (1) 2 (3) 2 (1)
 4 0 0 0 1 (<1) 0 1 (0) 0 0
Metastatic site, n (%) a         
 Liver 69 (66) 849 (73) 73 (70) 253 (69) 98 (67) 1014 (73) 44 (70) 88 (64)
 Lung 29 (28) 323 (28) 31 (30) 100 (27) 42 (29) 385 (28) 18 (29) 38 (28)
 Bone 1 (1) 45 (4) 2 (2) 8 (2) 2 (1) 50 (4) 1 (2) 3 (2)
 Other 32 (30) 311 (27) 22 (21) 82 (22) 41 (28) 361 (25) 14 (22) 32 (23)
No. of metastatic sites, n (%) (n = 100) (n = 1105) (n = 102) (n = 335) (n = 140) (n = 1317) (n = 62) (n = 123)
 1 73 (73) 732 (66) 78 (76) 238 (71) 104 (74) 883 (67) 47 (76) 87 (71)
 >1 27 (27) 373 (34) 24 (24) 97 (29) 36 (26) 434 (33) 15 (24) 36 (29)
Local recurrence, % 44 (45) 526 (51) 40 (42) 176 (53) 58 (42) 638 (51) 26 (46) 64 (51)
Median CEA, ng/mL (range) (n = 92) (n = 926) (n = 91) (n = 302) (n = 126) (n = 1113) (n = 57) (n = 115)
19.8 (0.4–3312.7) 21.2 (0–14671) 13.7 (0.1–1175) 21.9 (0.7–25305) 17.2 (0.4–3312.7) 20.9 (0–25305) 22.7 (0.1–1175) 25.6 (0.7–6848)
Prior chemotherapy, n (%) (n = 53) (n = 670) (n = 47) (n = 190) (n = 73) (n = 786) (n = 27) (n = 74)
 Adjuvant 35 (66) 453 (68) 33 (70) 127 (67) 47 (64) 534 (68) 21 (78) 46 (62)
 Neoadjuvant 9 (17) 67 (10) 2 (4) 24 (13) 10 (14) 79 (10) 1 (4) 12 (16)
  1. CEA, carcinoembryonic antigen; ECOG, Eastern Cooperative Oncology Group. aPatients could have >1 metastatic site.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us